{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:58:46Z","timestamp":1789167526132,"version":"build-2803163510"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n                           <jats:sup>177<\/jats:sup>Lu-PSMA radioligand therapy (RLT) has shown very encouraging results in metastatic castrate-resistant prostate cancer (mCRPC) patients with acceptable adverse events. The adverse events of RLT are mainly limited to salivary glands and kidneys. However, there is dearth of available data of RLT in transplanted kidney patients with mCRPC. Here is a case of 68-year-old mCRPC patient with history of renal transplant who underwent 4 cycles of <jats:sup>177<\/jats:sup>Lu-PSMA-617 RLT (~7.4 GBq\/cycle). Posttherapy serum creatinine and glomerular filtration rate remained stable along with excellent response and symptomatic improvement, thus demonstrating the safety of full dose of <jats:sup>177<\/jats:sup>Lu-PSMA in renal transplant patients.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004781","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T21:31:31Z","timestamp":1691789491000},"page":"e470-e471","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Excellent Response to Full-Dose 177Lu-PSMA-617 RLT in Metastatic Castration-Resistant Prostate Cancer With Transplant Kidney"],"prefix":"10.1097","volume":"48","author":[{"given":"Raza Abbas","family":"Mahdi","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fortis Hospital, Ludhiana, Punjab, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/cancers13123095","article-title":"Renal safety of [177Lu]Lu-PSMA-617 radioligand therapy in patients with compromised baseline kidney function","volume":"13","year":"2021","journal-title":"Cancer"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/ckj\/sfz101","article-title":"Renal outcomes of radioligand therapy: experience of 177lutetium\u2014prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer","volume":"13","year":"2020","journal-title":"Clin Kidney J"},{"issue":"supplement 1","key":"bib4-20250621","first-page":"1279","article-title":"Renal function after radioligand treatment with 177Lu-PSMA-617","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2967\/jnumed.118.223149","article-title":"177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2022.05.025","article-title":"Extensive 177Lu-PSMA radioligand therapy can lead to radiation nephropathy with a renal thrombotic microangiopathy\u2013like picture","volume":"83","year":"2023","journal-title":"Eur Urol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/RLU.0000000000002508","article-title":"Excellent response to lower dose of 177Lu-PSMA-617 in a metastatic castration\u2013resistant prostate cancer patient with a transplanted kidney","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1097\/RLU.0000000000003912","article-title":"Excellent response to adapted low-dose 177Lu-PSMA-617 PSMA therapy in renal compromise patient","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12149-021-01593-9","article-title":"Predictive factors of tumor sink effect: insights from 177Lu-prostate-specific membrane antigen therapy","volume":"35","year":"2021","journal-title":"Ann Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2967\/jnumed.121.261906","article-title":"Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality?","volume":"63","year":"2022","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:00:21Z","timestamp":1750532421000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004781"}},"subtitle":["A Step Ahead"],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004781","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,3]]}}}